One CRISPR treatment cut "bad" cholesterol in half for a full year

A single dose of an experimental CRISPR therapy lowered LDL cholesterol and triglycerides by about half in patients with difficult-to-treat lipid disorders, with reductions still present one year later. At the highest dose, LDL fell 52.5% and triglycerides fell 47.8%; the therapy remains experimental.

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.